Dr. Treon is listed by US News & World Report as being in the top 1%
of all doctors in the United States for his specialty.

Please visit our main program website:
Bing Center for Waldenstrom's Macroglobulinemia. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.

WM Workshops: Starting with the first International
Workshop for WM in Washington DC in Sept. 2000, worshops have been
held bi-annually, the most recent in August 2014 in
London, UK. These workshops provide a venue for the WM
scientific community to collaborate and share their latest research
with the goal of advancing the knowledge of the genetic basis and
pathogenesis of WM, and the development of theraputics for this
malignancy. To learn more, please visit our WM Workshop Website.

Patient/Physician Summits: Starting with the first summit in
Boston in November, 2001, these conferences have provided a valuable
opportunity for patients, their families and caregivers to meet
face-to-face with the leaders of the WM scientific community. They
can learn the latest developments in the research and treatment of
WM, and also participate in working sessions and panel discussions.
To learn more, please visit our WM
Summit Website.

MYD88 L265P is a commonly recurring mutation in patients with
Waldenström’s macroglobulinemia that can be useful in differentiating
Waldenström’s macroglobulinemia and non-IgM LPL from B-cell disorders that have
some of the same features. Click the graphic to download this groundbreaking
NEJM publication.

Dedicated to the Discovery of the Cause and Cure of Waldenstrom's Macroglobulinemia

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia and an Attending Physician for the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

Dr. Treon received a medical degree with honors from the Boston University School of Medicine, and a master’s degree in biochemistry and a doctorate of philosophy in tumor immunology from the graduate school at Boston University Medical Center. Dr Treon completed an internship and residency in internal medicine at Boston University Medical Center. He also completed a clinical fellowship in hematology and oncology at the Massachusetts General Hospital and a research fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine (ABIM) in Internal Medicine and Medical Oncology, and continues to maintain his ABIM certification in Medical Oncology.

Dr. Treon’s research interests are focused on understanding the genetic basis and pathogenesis of Waldenström’s Macroglobulinemia (WM), and the development of targeted therapeutics for this malignancy. Using whole genome sequencing, the Treon laboratory discovered the highly prevalent MYD88 L265P and CXCR4 WHIM mutations in WM, permitting the development of diagnostic molecular testing and targeted treatments for WM. Signaling work performed in the Treon laboratory established the critical role of Bruton’s Tyrosine Kinase (BTK) as a key mediator of MYD88 signaling in WM cells. This discovery enabled the first ever breakthrough designation by the U.S. FDA for the accelerated approval of the BTK inhibitor ibrutinib for the treatment of WM. Dr. Treon served as the principal investigator of the pivotal trial that supported the regulatory approval of ibrutinib by the U.S. FDA and European Medicines Agency for the treatment of WM. He has also been the principal investigator for other clinical trials that resulted in the adoption of many novel therapeutics and combination therapies for the treatment of WM.

Dr. Treon has published over 250 original articles, reviews, reports, and book chapters that have appeared in many high impact journals and text books. He has been a keynote speaker and lecturer on the genomic basis, pathogenesis, clinical features, and treatment of WM at prestigious national congresses, international conferences, hospital grand rounds, tumor boards, regional medical society conferences, workshops, and patient meetings. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, European Society of Hematology, and the British Society of Hematology, and has given “Meet the Professor”, Educational Session, as well as presentations on original research at the annual meetings of these associations. Dr. Treon is also the principal organizer of the International Workshops on WM which have served as the principal forum for the exchange of novel scientific and clinical data on WM. He has been a mentor to physicians and scientists at the Bing Center for WM, and is also a regular lecturer at Harvard Medical School and its affiliated hospitals where he teaches medical students, interns, residents and fellows on the topic of plasma cell malignancies.

For his clinical and research efforts, Dr. Treon has received awards from various organizations including an ASCO Young Investigator Award, the Robert A. Kyle Award, the Jan Gosta Waldenstrom Lifetime Achievement Award, the Laurie Strauss Leukemia Society Outstanding Cancer Investigator Award, designation as “America’s Top Doctor” by U.S. News and World Report, and the “One-Hundred Award” from the Massachusetts General Hospital. In 2011, and 2013, Dr. Treon’s research work received “Best of ASH” designations at the Annual Meeting of the American Society of Hematology.

August, 2014, London, UK: The
8th International Workshop for Waldenstrom's Macroglobulinemia and
Symposium on Advances in Multiple Myeloma was held from August
13-17, 2014 at the Park Plaza Westminster Hotel, in beautiful
historic London, UK. The workshop was attended by over 200
scientists and research staff, representing 20 countries. IWWM-8
included 12 sessions with 50 technical presentations, 8 "Great
Debates" (4-MM, 4-WM), 38 poster presentations, including a 2-hour
poster session with short oral presentations of accepted posters, a
special Saturday luncheon lecture by Dr. Shirley D'Sa, and 4 "Task
Force" discussions on various topics in WM. Opening & Closing
ceremonies included the awarding of the 2014 Robert Kyle award to
Dr. Roger Owen, and the 2014 Waldenstrom Award was shared between
Drs. Enrica Morra and Morie Gertz.